Pacira Pharmaceuticals (PCRX)

10.62 -0.05  -0.47%  May 31, 8:00PM Go Pro
Watch this stock
View Full Chart PCRX Price Chart

Key Stats

Market Cap 269.85M
Revenue Growth 102.0%
Profit Margin -152.4%
Earnings Yield -20.06%
Dividend Yield 0.00%
Earnings Per Share TTM -2.13
PE Ratio
Price / Sales Ratio 13.75
52 Week High 14.75
52 Week Low 6.51
Beta
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 29 $AMRN $pcrx Lots of charts showing real accumulation at the EOD today.. Good sign in my opinion by turrable
May 29 $PCRX its coiling for its next big move and thats up IMO by turrable
May 29 Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Confe...
May 25 Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX Street Insider
May 24 $AMRN and $PCRX are my 2 potential home runs. I can honestly say $PCRX is an absolute game changer in the operative setting. by turrable
May 21 $PCRX Pacira Pharmaceuticals Inc. To Be Added To NASDAQ Biotechnology Index by johnkelly
May 21 Pacira Pharmaceuticals, Inc. to Be Added to NASDAQ Biotechnology Index Business Wire
May 18 PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agr...
May 15 Let's see if $PCRX can break through this $11 level... been struggling with it a bit. by jckund
May 15 10 biotech securities will be added to the Nasdaq biotech index on May 21: $CERS $CLDX $FOLD $INFI $JAZZ $OMER $OREX $PCRX $RPTP $TSRX by abubnic
May 10 Oxford Finance Provides $27.5 Million Debt Financing Facility to Pacira Pharmaceutica...

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Drug Manufacturers - Major

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Pacira Pharmaceuticals is down 25.73% over the last year vs S&P 500 Total Return up 0.88%, WuXi PharmaTech down 19.34%, and Endocyte down 46.13%.

  • PCRX Total Returns
  • ^SPXTR Total Returns
  • WX Total Returns
  • ECYT Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Get Quote for

Pro Strategies Featuring PCRX

Did Pacira Pharmaceuticals make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

PCRX Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
PCRX 10.62 -0.05 -0.47% 271.12M
PCP 166.21 -0.41 -0.25% 24.19B
PCOM 11.27 +0.05 +0.45% 169.09M
PCN 16.19 +0.09 +0.56%
PCM 10.94 -0.03 -0.27%
PCLN 625.49 -12.27 -1.92% 31.76B
PBY 9.28 +0.39 +4.39% 468.95M
PBTH 5.09 +0.07 +1.39% 273.79M
PBT 17.64 -0.45 -2.49% 843.17M
PBSK 12.07 +0.00 +0.00%
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close